NASDAQ:IMGN
ImmunoGen Stock News
$31.23
+0 (+0%)
At Close: Apr 26, 2024
AbbVie Cuts Its Guidance on ImmunoGen Deal
12:20pm, Monday, 12'th Feb 2024
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
07:51am, Monday, 12'th Feb 2024
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The co
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
10:40am, Friday, 09'th Feb 2024
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
07:01am, Friday, 09'th Feb 2024
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
02:38pm, Tuesday, 06'th Feb 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a k
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
09:01am, Tuesday, 09'th Jan 2024
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
01:32pm, Thursday, 04'th Jan 2024
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for January 4th
08:17am, Thursday, 04'th Jan 2024
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
08:30am, Tuesday, 26'th Dec 2023
AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.
3 Stocks at the Forefront of Medical Innovation
08:23pm, Monday, 25'th Dec 2023
Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments
5 Reasons to be Bullish into 2024
04:32pm, Monday, 11'th Dec 2023
2023: Predicting is Futile, Interpreting is Priceless
Market Movers: Why Big Players Are Investing Millions in These 3 Stocks
11:23am, Friday, 08'th Dec 2023
Certain smart money stocks catch the discerning eye of big players in investing, drawing in substantial investments. Delving into the strategies and growth patterns of three companies reveals intrigui
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout
09:51am, Thursday, 07'th Dec 2023
U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
03:26pm, Wednesday, 06'th Dec 2023
Small-cap stocks are a good option for investors looking to gain exposure to typically newer companies offering niche products and services that may have the potential for massive share price apprecia
Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice
01:32pm, Monday, 04'th Dec 2023
Does ImmunoGen (IMGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
